Linkage between Twist1 and Bmi1: Molecular mechanism of cancer metastasis/stemness and clinical implications

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 8, 2012, Pages 668-673

  Wu, Chung Yin ^a   Hung, Jung Jyh ^b   Wu, Kou Juey ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bmi1; Cancer stemness; Epithelial mesenchymal transition; Metastasis; Twist1

Indexed keywords

BMI1 PROTEIN; TRANSCRIPTION FACTOR TWIST;

ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CANCER STEMNESS; CELL RENEWAL; DRUG MECHANISM; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; METASTASIS; PROTEIN EXPRESSION;

ANIMALS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 1; TWIST TRANSCRIPTION FACTOR;

EID: 84864316541     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05594.x     Document Type: Article

References (77)

1. Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX. Metastasis: The seed and soil theory gains identity. Cancer Metastasis Rev. 2007; 26: 705-15.
2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 2008; 14: 818-29.
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
4. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?Nat. Rev. Cancer 2007; 7: 415-28.
5. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle 2008; 7: 2090-6.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
7. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: Mirage or reality?Nat. Med. 2009; 15: 1010-2.
8. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010; 16: 3113-20.
9. Castanon I, Baylies MK. Twist in fate. Evolutionary comparison of Twist structure and function. Gene 2002; 287: 11-22.
10. Furlong EE, Andersen EC, Null B et al. Patterns of gene expression during Drosophila mesoderm development. Science 2001; 293: 1629-33.
11. Yang J, Mani S, Donaher J et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39.
12. Yang MH, Wu MZ, Chiou SH et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008; 10: 295-305.
13. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states. Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009; 9: 265-73.
14. Blick T, Hugo H, Widodo E et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 (hi/) CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010; 15: 235-52.
15. Mimeault M, Batra SK. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol. Histopathol. 2010; 25: 1057-73.
16. Pietersen AM, van Lohuizen M. Stem cell regulation by polycomb repressors: Postponing commitment. Curr. Opin. Cell Biol. 2008; 20: 201-7.
17. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J. Clin. Invest. 2004; 113: 175-9.
18. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999; 13: 2678-90.
19. Iwama A, Oguro H, Negishi M et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004; 21: 843-51.
20. Fasano CA, Phoenix TN, Kokovay E et al. Bmi-1 cooperates with Foxg1 to maintain neural stem cell self-renewal in the forebrain. Genes Dev. 2009; 23: 561-74.
21. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 2008; 40: 915-20.
22. Pietersen AM, Evers B, Prasad AA et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr. Biol. 2008; 18: 1094-9.
23. Dhawan S, Tschen SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev. 2009; 23: 906-11.
24. Min J, Zhang Y, Xu RM. Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev. 2003; 17: 1823-8.
25. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat. Rev. Mol. Cell Biol. 2006; 7: 667-77.
26. Battula VL, Evans KW, Hollier BG et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 2010; 28: 1435-45.
27. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
28. Liu M, Casimiro MC, Wang C et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc. Natl Acad. Sci. USA 2009; 106: 19035-9.
29. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-64.
30. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 2007; 104: 973-8.
31. Yang MH, Hsu DS, Wang HW et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 2010; 12: 982-92.
32. Cao Q, Yu J, Dhanasekaran SM et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-84.
33. Lukacs RU, Memarzadeh S, Wu H, Witte ON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010; 7: 682-93.
34. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-59.
35. Okada T, Suehiro Y, Ueno K et al. TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosom. Cancer 2010; 49: 452-62.
36. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol. 2004; 24: 306-19.
37. Herranz N, Pasini D, Díaz VM et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 2008; 28: 4772-81.
38. Ansieau S, Bastid J, Doreau A et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79-89.
39. Dimri GP, Martinez JL, Jacobs JJ et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002; 62: 4736-45.
40. Song LB, Li J, Liao WT et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 2009; 119: 3626-36.
41. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 2010; 10: 268-78.
42. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010; 70: 3005-8.
43. Qin L, Zhang X, Zhang L et al. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 2008; 371: 531-5.
44. Alajez NM, Shi W, Hui AB et al. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ. 2009; 16: 1469-79.
45. Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL. BMI1 Silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int. J. Cancer 2010; 128: 1946-54.
46. Wu X, Liu X, Sengupta J et al. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J. Exp. Biol. 2011; 49: 105-12.
47. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J. Oral Pathol. Med. 2011; Epub 22 February 2011; doi:.
48. Li J, Gong LY, Song LB et al. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am. J. Pathol. 2010; 176: 699-709.
49. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J. Neurosci. 2010; 30: 10096-111.
50. Raimondi C, Gianni W, Cortesi E, Gazzaniga P. Cancer stem cells and epithelial-mesenchymal transition: Revisiting minimal residual disease. Curr. Cancer Drug Targets 2010; 10: 496-508.
51. Guo BH, Feng Y, Zhang R et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol. Cancer 2011; 10: 10.
52. Zhang X, Wang CX, Zhu CB et al. Overexpression of Bmi-1 in uterine cervical cancer: Correlation with clinicopathology and prognosis. Int. J. Gynecol. Cancer 2010; 20: 1597-603.
53. Liu JH, Song LB, Zhang X et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J. Surg. Oncol. 2008; 97: 267-72.
54. Yonemitsu Y, Imazeki F, Chiba T et al. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum. Pathol. 2009; 40: 1304-11.
55. Vrzalikova K, Skarda J, Ehrmann J et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: A tissue microarray study. J. Cancer Res. Clin. Oncol. 2008; 134: 1037-42.
56. Zhang XY, Dong QG, Huang JS et al. The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J. Surg. Oncol. 2010; 102: 856-62.
57. Li DW, Tang HM, Fan JW et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J. Cancer Res. Clin. Oncol. 2010; 136: 997-1006.
58. Qin ZK, Yang JA, Ye YL et al. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 2009; 9: 61.
59. He XT, Cao XF, Ji L et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J. Gastroenterol. 2009; 15: 2389-94.
60. Yang GF, He WP, Cai MY et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 2010; 10: 133.
61. Bhattacharyya J, Mihara K, Yasunaga S et al. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann. Hematol. 2009; 88: 333-40.
62. Zakrzewska M, Zakrzewski K, Grešner SM, Piaskowski S, Zalewska-Szewczyk B, Liberski PP. Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma. Childs Nerv. Syst. 2011; 27: 79-86.
63. Hoenerhoff MJ, Chu I, Barkan D et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009; 28: 3022-32.
64. Boukarabila H, Saurin AJ, Batsché E et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 2009; 23: 1195-206.
65. Rizo A, Horton SJ, Olthof S et al. BMI. 1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 2010; 116: 4621-30.
66. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 2005; 12: 488-96.
67. Shibata K, Kajiyama H, Ino K et al. Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann. Oncol. 2008; 19: 81-5.
68. Rosivatz E, Becker I, Specht K et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 2002; 161: 1881-91.
69. Lee TK, Poon RT, Yuen AP et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 2006; 12: 5369-76.
70. Sun T, Zhao N, Zhao XL et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry. Hepatology 2010; 51: 545-56.
71. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1a, TWIST1, and Snail expression in resectable non-small cell lung cancer. Thorax 2009; 64: 1082-9.
72. Valdés-Mora F, Gómez del Pulgar T, Bandrés E et al. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann. Surg. Oncol. 2009; 16: 78-87.
73. Yu Q, Zhang K, Wang X et al. Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J. Exp. Clin. Cancer Res. 2010; 29: 119.
74. Yuen HF, Chan YP, Wong ML et al. Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J. Clin. Pathol. 2007; 60: 510-4.
75. Xie F, Li K, Ouyang X. Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin. Exp. Metastasis 2009; 26: 1025-32.
76. Yoshida J, Horiuchi A, Kikuchi N et al. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: The important role of Snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 2009; 42: 82-91.
77. Kwok WK, Ling MT, Lee TW et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005; 65: 5153-62.